A Phase II NCCTG Study of Irinotecan and Docetaxel in Previously Treated Patients with Non-Small Cell Lung Cancer

Author： Molina Julian   Nikcevich Daniel   Hillman Shauna   Geyer Susan   Drevyanko Timothy   Jett James   Verdirame Joseph   Tazelaar Henry   Rowland Kendrith   Wos Edward   Kutteh Leila   Nair Suresh   Fitch Tom   Flynn Patrick   Stella Philip   Adjei Alex  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.24, Iss.4, 2006-07, pp. : 382-389

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study

By                        

Oncology Letters, Vol. 3, Iss. 4, 2012-01 ,pp. : 761-766

Spandidos Publications

Access to resources Recommend Favorite

Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer

By Yanagihara Kazuhiro   Yoshimura Kenichi   Niimi Miyuki   Yasuda Hiroyasu   Sasaki Takahiko   Nishimura Takafumi   Ishiguro Hiroshi   Matsumoto Shigemi   Kitano Toshiyuki   Kanai Masashi   Misawa Akiko   Tada Harue   Teramukai Satoshi   Mio Tadashi   Fukushima Masanori  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 913-918

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer

By Hirose Takashi   Shirai Takao   Ishida Hiroo   Ando Kohichi   Sugiyama Tomohide   Kusumoto Sojiro   Hosaka Takamichi   Nakashima Masanao   Ohmori Tohru   Adachi Mitsuru  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 267-274

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer

By Tomonaga Nanae   Nakamura Yoichi   Soda Hiroshi   Nagashima Seiji   Nakano Hirofumi   Kinoshita Akitoshi   Fukuda Masaaki   Fukuda Minoru   Takatani Hiroshi   Soejima Yoshifumi   Oka Mikio   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 43-49

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer

By Lam Elaine   Au Jessie   Otterson Gregory   Guillaume Wientjes M.   Chen Ling   Shen Tong   Wei Yong   Li Xiaobai   Bekaii-Saab Tanios   Murgo Anthony   Jensen Rhonda   Grever Michael   Villalona-Calero Miguel  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1019-1029

Springer Publishing Company

Access to resources Recommend Favorite